The Future of TAVR in Asia

TAVR bioprosthetic heart valve market to grow between 20-25% in east Asia

Transcatheter aortic valve replacements (TAVR) is set to be one of the fastest-growing procedural areas in cardiac surgery for Asia. Opportunities are growing particularly in east Asia as the number of TAVR candidates rises in an aging population, and with an expanding indication towards younger, lower-risk patients.

TAVR procedural volume to grow rapidly in Asia between 2022-2025

The volume of TAVR procedures in the region is growing rapidly as infrastructure and the level of procedural expertise matures. The number of hospitals performing TAVR has also increased significantly in countries such as Japan and China. More mid-sized secondary hospitals are now also capable of carrying out TAVR procedures and there is more room to grow. 

Explore opportunity and openings in the TAVR market 

The underpenetration of TAVR in Asia’s large population presents a gap for market players. Clearstate expects Asia’s market for bioprosthetic heart valves for TAVR procedures to grow strongly, with countries in east Asia tracking an average annual growth rate of 25% to 50% between 2020-2025.

Medtech firms need to understand Asia’s TAVR market landscape and the strategy implications that could enable improvements in TAVR access for the region.

For more on the TAVR market, download the report on The Future of TAVR in Asia

Through Economist Intelligence Clearstate’s team of consultants and Surgical Gateway – our proprietary data solution, we support your strategic and tactical business planning, and provide answers on gaining market share.

Make an inquiry

To find out how Clearstate services can help your organisation, get in touch by submitting the form below.

Surgical Gateway

The go-to-source of market data and insights on surgical procedure volume and surgical device size and share.